-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder
.
Its main clinical manifestations include abdominal pain, bloating, and changes in bowel habits (diarrhea, constipation), and the pathogenesis of the disease is unclear, so the diagnosis of IBS is mainly based on clinical symptoms
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder
The researchers assigned IBS-D patients to receive moxibustion or sham moxibustion (52 treatments each, 3 times a week for 6 weeks) and followed up for 24 weeks
.
The acupoints were selected bilaterally ST25 and ST36, and the body surface temperature of each acupoint in the moxibustion group and the sham operation group were 43℃±1℃ and 37℃±1℃, respectively
According to intention-to-treat analysis, the incidence of IBS-AR in the moxibustion group was significantly higher than that in the sham operation group at 6 weeks (76.
9% vs 42.
3%; p < 0.
001); the average decrease in the total score of IBS-BSS in the moxibustion group was lower than that in the moxibustion group.
In the sham group (-116.
9 VS -61.
5; p < 0.
001), both remained unchanged throughout follow-up
.
At week 6, the rate of >50-point reduction in IBS-SSS was significantly higher in the treatment group than in the sham group (p < 0.
Photo: Degree in Moxibustion
This study demonstrated that moxibustion for ST25 and ST36 was associated with sustained beneficial clinical effects when treating IBS-D patients for at least 24 weeks
.
Moxibustion therapy is beneficial for long-term relief of symptoms in patients with IBS-D
This study demonstrated that moxibustion for ST25 and ST36 was associated with sustained beneficial clinical effects when treating IBS-D patients for at least 24 weeks
Original source:
Chunhui Bao.
Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial.
Leave a comment here